Neuren Pharmaceuticals

Profilo dell'azienda

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Descrizione disponibile in inglese.

Dati societari

Settore

Salute

Industria

Biotechnology

Paese

Australia

Sede

117 Camberwell Road, 3123, Hawthorn East

Quotazione

NEU · ASX

Indici

S&P/ASX 200

Valuta

AUD

ISIN

NZNEUE0001S8

Sito web

neurenpharma.com